Samuel Denmeade, MD
![Samuel Denmeade, MD](https://res.cloudinary.com/pcf/images/w_150,h_225,c_scale/fl_lossy/f_auto,q_auto/v1674666189/Samuel-Denmeade-MD-from-google_5526352a3/Samuel-Denmeade-MD-from-google_5526352a3.jpg?_i=AA)
About Samuel Denmeade, MD
Evaluation of Bindarit, a Novel Inhibitor of the CCL2 Chemokine Axis, as Therapy for Metastatic Prostate Cancer
Dr. Denmeade is testing a medication called Bindarit – an orally active compound already tested in over 500 patients. Bindarit affects a number of mediators of chemotherapy resistance, especially in bone. Preclinical studies will be performed to qualify Bindarit for testing in men with metastatic prostate cancer.
Potential patient benefit: Bindarit may represent a new and novel tumor microenvironment therapy for men with metastatic prostate cancer and holds the potential to improve the efficacy of chemotherapy.
Award
The Movember-PCF Creativity Award
Designation
Professor, Pharmacology & Molecular Sciences
University
The Johns Hopkins University School of Medicine